Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01576172 · ClinicalTrials.gov registry record · Phase 2
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
NCT01576172: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01576172 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 159 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01576172, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
Study Summary
This randomized phase II trial studies abiraterone acetate and prednisone together with veliparib to see how well it works compared to abiraterone acetate and prednisone alone in treating patients with castration-resistant prostate cancer that has spread from the primary site to other places in the body. Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving abiraterone acetate together with prednisone and veliparib may work better than abiraterone acetate and prednisone alone in treating patients with castration-resistant prostate cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Prednisone
- DRUG Abiraterone Acetate
- DRUG Veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2012-03-30 |
| Est. Completion | 2020-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01576172
The ClinicalTrials.gov registry entry for NCT01576172 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01576172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01576172 about?
NCT01576172 is a clinical study titled "Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer". This randomized phase II trial studies abiraterone acetate and prednisone together with veliparib to see how well it works compared to abiraterone acetate and prednisone alone in treating patients with castration-resistant prostate cancer that has spread from the primary site to other places in the ...
What is the current status of trial NCT01576172?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2012-03-30. Estimated completion is 2020-04-23.
What interventions are being tested in trial NCT01576172?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Prednisone (DRUG), Abiraterone Acetate (DRUG), Veliparib (DRUG).
Who is sponsoring clinical trial NCT01576172?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.